Newborn screening programs are the best way to diagnose Fabry disease early in infancy — enabling timely enzyme replacement therapy…
Ana Pena, PhD
Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Certain cells in patients with Fabry disease seem to age more rapidly than in healthy people, which may explain…
Rats that mimic Fabry disease develop eye symptoms like those observed in human patients. These animals can be used to…
Few nephrologists in Russia are aware of Fabry disease, which is a problem that could be addressed by…
Obstructive Sleep Apnea Not More Severe or Frequent in Patients with Mild Fabry Disease, Study Says
Patients with mild Fabry disease do not have a higher prevalence or severity of …
Although most women with Fabry disease have mild but typical manifestations, many are not…
Newborn screening with enzymatic testing can effectively detect Fabry disease in infants, a…
Genetic and enzymatic screening of people in Spain revealed that the real prevalence of Fabry disease is likely…
A specific mutation in the GLA gene is associated with late-onset Fabry disease, and primarily affects…
Personalized care with timely treatment and regular monitoring should be given to adults with Fabry disease to prevent irreversible…